Colorectal Cancer

Latest News

Rideshare | Image credit: terovesalainen - stock.adobe.com
Rideshare Cuts Colon Cancer Deaths, Saves Costs After Abnormal FIT, Study Finds

September 4th 2025

A study finds that $100 rideshare rides for follow-up colonoscopy after fecal immunochemical test (FIT) doubled completion rates, reduced colorectal cancer (CRC) deaths, and lowered health care costs.

CRC detection | Image credit: Ahmet Aglamaz - stock.adobe.com
AI Model Using EHR Data Predicts 5-Year Survival in Colorectal Cancer

August 19th 2025

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg
Comfort, Targeted Nursing Boost Recovery in Colorectal Surgery

August 18th 2025

FIT test | Image credit: TOimages - stock.adobe.com
Pharmacy-Based FIT Screening Could Boost Colorectal Cancer Detection

August 15th 2025

Berberine | Image credit: Oleksandr - stock.adobe.com
Berberine Shows Lasting Protection Against Colorectal Adenoma Recurrence

August 13th 2025

More News

Webinar Highlights Recommendations to Improve Disparities in CRC Screening
October 18th 2023

Webinar Highlights Recommendations to Improve Disparities in CRC Screening

Julia Bonavitacola
Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.
Clinical Staging of Colorectal Cancer Increased in Post–COVID-19 Period
October 12th 2023

Clinical Staging of Colorectal Cancer Increased in Post–COVID-19 Period

Julia Bonavitacola
Significant increases in clinical staging for colorectal cancer were found when evaluating the extended timeframes beyond pre– and post–COVID-19 periods.
Video Intervention Increased CRC Screening in Somali-Speaking Patients
October 9th 2023

Video Intervention Increased CRC Screening in Somali-Speaking Patients

Julia Bonavitacola
Patients who spoke Somali were more willing to get a screening for colorectal cancer (CRC) after a video intervention.
In-Person Interactions Key to Improve CRC Screening Rates in African American Individuals
October 6th 2023

In-Person Interactions Key to Improve CRC Screening Rates in African American Individuals

Julia Bonavitacola
Successfully increasing colorectal cancer screening rates in African Americans could be achieved through the key roles of in-person interactions and community contexts.
Symptom Distress, Depression, Lower Social Support Found in Younger Patients With CRC and Stoma
October 3rd 2023

Symptom Distress, Depression, Lower Social Support Found in Younger Patients With CRC and Stoma

Julia Bonavitacola
Younger patients who had colorectal cancer (CRC) stoma had more symptom distress, were depressed and anxious, and had higher supportive care needs.
Low Exercise, Sarcopenia, Myosteatosis Associated With CRC-Specific Mortality
September 30th 2023

Low Exercise, Sarcopenia, Myosteatosis Associated With CRC-Specific Mortality

Julia Bonavitacola
Sarcopenia or myosteatosis combined with low prediagnostic physical exercise was associated with increased mortality from colorectal cancer (CRC).
Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC
September 28th 2023

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

Chris Ryan
The integration of novel mRNA biomarkers into the ColoAlert screening test resulted in high sensitivity and specificity for detecting colorectal cancer (CRC).
Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib
September 26th 2023

Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib

Julia Bonavitacola
Although nofazinlimab was well tolerated and showed antitumor activity in many tumor types, no response was found when combined with regorafenib to treat metastatic colorectal cancer (mCRC).
Unmeasured Social Context Could Explain Racial Differences in Screening for CRC
September 19th 2023

Unmeasured Social Context Could Explain Racial Differences in Screening for CRC

Julia Bonavitacola
Screening for colorectal cancer (CRC) is defined by racial differences, which could be explained through social context.
Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years
September 18th 2023

Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years

Julia Bonavitacola
Although mortality and disability-adjusted life-years remained stable, the prevalence and incidence of early-onset colorectal cancer (CRC) increased globally in individuals aged 40 to 49 years.
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC
September 15th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

Caroline Seymour
The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.
Man waist measured
September 7th 2023

Visceral Obesity Associated With Anastomotic Leakage After Colon Cancer Surgery

Julia Bonavitacola
A significant relationship between visceral obesity and anastomotic leakage was found, which indicates that visceral obesity could be a risk factor in surgery for colon cancer.
tumor cell
September 4th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

Kyle Doherty
Circulating tumor DNA (ctDNA) status at the time of postoperative minimal residual disease assessment is a prognostic factor for disease-free survival (DFS) in patients with radically resected stage II to IV colorectal cancer (CRC).
Illustrated colorectal image | Credit: mi_viri - stock.adobe.com
August 28th 2023

HER2 Amplification Shows Prognostic Capabilities in mCRC

Megan Hollasch
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Doctor projects the human large intestine on the tablet. Study and analysis of colon cancer, bacteria, inflammation, ulcerative colitis, colonoscopy, diverticulosis. Health technology development: © Tom - stock.adobe.com
August 25th 2023

Personalized CRC Screening Remains Elusive, Requires Careful Planning

Maggie L. Shaw
Three sessions of a semi-structured focus group were conducted to gain patient feedback on personalized screening for colorectal cancer (CRC).
paper people of different colors
August 18th 2023

Time to Treatment Initiation Affected by Demographics, Socioeconomics in CRC, NSCLC

Kyle Doherty
Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.
AJMC
August 16th 2023

Social Determinants of Health: Are Colonoscopies Always Fit for Duty?

Benjamin K. Stone, MSc Jonathan I. Gates, MD Kristina A. Monteiro, PhD
Social determinants of health are associated with colonoscopy noncompletion in a Medicaid patient population at the Providence Community Health Centers.
black doctor speaking to older white male patient
August 10th 2023

Increases in Cancer Screenings, Chronic Condition Diagnoses in First Year of Medicare Coverage

Laura Joszt, MA
Patients were twice as likely to get a colorectal cancer screening and 50% more likely to get a breast cancer screening in their first year of Medicare coverage.
rendering of the colon above doctor's hands
August 3rd 2023

Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults

Laura Joszt, MA
Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
FDA approved red stamp on white background
August 2nd 2023

FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Kristi Rosa
The FDA approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who had previously been treated based on data from the phase 3 SUNLIGHT trial.
AJMC
July 27th 2023

A “Sludge Audit” for Health System Colorectal Cancer Screening Services

Michelle S. Rockwell, PhD, RD Mary C. Frazier, BS Jeffrey S. Stein, PhD Kimberly A. Dulaney, MD Sarah H. Parker, PhD George C. Davis, PhD John A. Rockwell, MS, MBA Benjamin L. Castleman, EdD Cass R. Sunstein, JD John W. Epling, MD, MSEd
A systematic, mixed methods “sludge audit” identified novel health system delivery targets for improving colorectal cancer screening services.
ASCO GI 2023: SUNLIGHT Study
March 14th 2023

ASCO GI 2023: SUNLIGHT Study

John L. Marshall, MD, provides insight into the SUNLIGHT study findings presented during the 2023 ASCO Gastrointestinal Cancers Symposium.
image of cancer cells
January 23rd 2023

Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer

Allison Inserro
Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as well as royalties on worldwide net sales, with the exception of mainland China, Hong Kong, and Macau.
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
January 19th 2023

Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC

Mary Caffrey
The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
Kristen K. Ciombor, MD, MSCI, associate professor, Vanderbilt University
December 24th 2022

Neoadjuvant Immunotherapy Promising in CRC, but Long-term Data Needed, Says Dr Kristen Ciombor

Pearl Steinzor
Kristen K Ciombor, MD, MSCI, associate professor at Vanderbilt University, explains that results of neoadjuvant immunotherapy in colorectal cancer are promising, but long-term data is still needed.
image of genes
December 22nd 2022

Large Genome-Wide Association Study Finds Possible New Colorectal Cancer Targets

Pearl Steinzor
A recent genome-wide association study found hundreds of genes linked to risk for colorectal cancer among a diverse worldwide population.
Kristen K. Ciombor, MD, MSCI, associate professor, Vanderbilt University
December 17th 2022

Dr Kristen Ciombor: Neoadjuvant Immunotherapy in CRC Reduces Need for Other Treatments

Pearl Steinzor
Kristen K. Ciombor, MD, MSCI, associate professor at Vanderbilt University discusses why neoadjuvant immunotherapy is superior to other immunotherapy treatments in colorectal cancer.
Evidence-Based Oncology logo
December 2nd 2022

From Cancer Prevention to Treatment: Underpinning the Advances, Challenges to Democratizing Precision Oncology

Matthew Gavidia
Coverage from the Institute for Value-Based Medicine® event in Nashville, Tennessee, held November 17, 2022. The event was held in partnership with Vanderbilt-Ingram Cancer Center.
Kristen K. Ciombor, MD, MSCI, associate professor of medicine, Vanderbilt University
December 2nd 2022

Dr Kristen Ciombor on Precision Medicine Approaches in Colorectal Cancer

Pearl Steinzor
Kristen K. Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt University, spoke on the need for precision medicine approaches in colorectal cancer.
What Does PD-L2 Tell Us About Advanced Colorectal Cancer?
December 30th 2020

What Does PD-L2 Tell Us About Advanced Colorectal Cancer?

Mary Caffrey
Results show the presence of PD-L2 in the tumor may be an independent predictor of survival outcomes for patients with advanced stage colon carcinoma.
<1234567>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo